Do you want to play a key role in improving the treatment options for patients with endometriosis and other inflammatory/pain conditions?
190 million women around the world have endometriosis, a significant health issue with a substantial need for better medical solutions. As awareness of the unmet needs in the women´s health area and the associated market potential is on the rise, Gesynta Pharma is well positioned to make a historical contribution in the treatment of endometriosis, as well as in other inflammatory/pain diseases. As Gesynta Pharma embarks on the next, critical step of this journey, the company expands its team by appointing the key position VP Clinical Development.
Located in central Stockholm, Sweden, Gesynta Pharma is a pharmaceutical company that develops unique drug candidates aiming to reduce harmful inflammation and pain. The company´s R&D platform is built on research originating from Karolinska Institutet. The company has successfully advanced a portfolio of drug candidates with a unique ability to selectively inhibit microsomal prostaglandin E synthase (mPGES-1), the enzyme that produces inflammation-promoting prostaglandin E2. By targeting mPGES-1 our lead drug candidate, vipoglanstat, attenuates endometriotic lesions while exerting potent anti-inflammatory and pain-relieving effects. With a favorable safety and pharmacology profile demonstrated in previous phase I and II trials, vipoglanstat is about to start a phase II study in patients with endometriosis. In addition to vipoglanstat the company portfolio comprises further mPGES-1 inhibitors, including GS-073. This drug candidate is ready to enter clinical development for the treatment of chronic inflammatory pain, another area of immense medical need.
We are looking for a VP Clinical Development with extensive experience in clinical development from R&D in the pharmaceutical or biotech industry. This position involves high level strategic planning as well as hands-on responsibility for overseeing the planning, execution, and management of clinical development programs for new drug candidates. You will report to the CEO and be a member of the executive and R&D management teams.
Please apply through our recruiting partner Haeger & Carlsson, haegercarlsson.com
Questions are answered by:
Gesynta Pharma bygger sin forskning på banbrytande forskning från Karolinska Institutet.
Vår välmeriterade ledning och styrelse har stor erfarenhet av läkemedelsutveckling, kommersialisering och företagsbyggande.
Endometrios är en kronisk, inflammatorisk, östrogenberoende sjukdom som drabbar miljoner kvinnor över hela världen.
Vår längst framskridna läkemedelskandidat vipoglanstat befinner sig i klinisk fas II, och GS-073 är redo för klinisk fas I.